Wednesday, February 10, 2010, 4:05am EST - Canadian Markets open in 5 hours and 25 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Neostem, Inc. (NBS)

 On Feb 9: 1.67 USD   0.00 (0.00%)  
MORE ON NBS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
NEOSTEM, INC. (AMEX:NBS) Delayed quote dataEdit
Last Trade: 1.67 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 1.67
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: N/A
Day's Range: N/A - N/A
52wk Range: 0.45 - 2.72
Volume: 0
Avg Vol (3m): 65,123.8
Market Cap: 62.11M
P/E (ttm): N/A
EPS (ttm): -2.13
Div & Yield: N/A (N/A%)
Neostem, Inc. (NBS)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add NBS to Portfolio   Download Data

HEADLINES
• Some Small Cap Biotech Stocks Worth Watching
at Seeking Alpha (Tue 10:10am)
• Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network
PRNewswire (Tue 8:00am)
• China Biotech Week in Review: New Investments in Life Science
at Seeking Alpha (Mon, Feb 8)
• Traders Send Select Stem Cell Shares Soaring
Indie Research (Mon, Feb 8)
• NeoStem Taps Chinese Healthcare Reform Profits
at Seeking Alpha (Wed, Feb 3)
• Tapping Into Chinese Healthcare Reform Profits with Neostem (Amex:NBS)
BayStreet Newswire (Tue, Feb 2)
• NeoStem's Eyre Subsidiary Approved to Use New Manufacturing Facility
at Seeking Alpha (Tue, Feb 2)
• NEOSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Mon, Feb 1)
• NeoStem's Suzhou Erye Pharmaceutical Subsidiary Receives Approval for First Two Manufacturing Lines in its New Facility
PRNewswire (Mon, Feb 1)
• China Biotech in Review: More Money Raised in China IPOs in 2009 than in the U.S.
at Seeking Alpha (Sun, Jan 31)
• NeoStem Receives SFDA Approval for Reflux Drug
at Seeking Alpha (Tue, Jan 26)
• Neostem: Ready to Take Off?
at Seeking Alpha (Mon, Jan 25)
• Slew of Stem Cell News Helps Sector Higher
Indie Research (Mon, Jan 25)
• NeoStem's Suzhou Erye Pharmaceutical Subsidiary Receives Approval to Manufacture Generic
PRNewswire (Mon, Jan 25)
• Biotech Bulls Becoming Restless
at Seeking Alpha (Sun, Jan 24)
• NeoStem: BioInsurance for the Future
at Seeking Alpha (Sun, Jan 24)
• CEO of NeoStem (NYSE Amex: NBS) Says China Will Play a Key Role in Company's Future
Marketwire (Wed, Jan 20)
• Taseko Mines, NeoStem: Midday Volume Plays
at TheStreet.com (Tue, Jan 19)
• NeoStem (AMEX: NBS) may be ahead of the stem cell treatment curve
BayStreet Newswire (Tue, Jan 19)
More Headlines for NBS...
ANALYST
EPS Est (next year) (Dec-69) : N/A
EPS Est (in 2 years) (Dec-69) : N/A
Avg Rec (current)*: N/A
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
NeoStem, Inc., together with its subsidiaries, operates a network of commercial autologous adult stem cell banks in the metropolitan areas of the United States.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices